Seaport Therapeutics ended Q3 with just north of $403 million, providing runway into 2029 ahead of a Glyph Allo top-line readout in the first half of 2027 and a Glyph-Ago Phase 2A readout in early 2028.
SPTX · Seaport Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since May 1, 2026; less than a full year is stored.
Up next
Latest documents
Seaport Therapeutics reported a $114.4 million nine-month net loss and $403.8 million in cash, cash equivalents and investments, which management believes will fund operations into 2029 after its IPO.
Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, versus $22.5 million a year earlier. Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, expected to fund operations into 2029.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and investments | 427.3M | as of June 30, 2026 | — |
| Glyph2BLSD | 1.62M | the three months ended June 30, 2026 filing | — |
| Glyph2BLSD direct research and development expenses | 1.62M | the three months ended June 30, 2026 filing | — |
| GlyphAgo | 3.48M | the three months ended June 30, 2026 filing | — |
| GlyphAgo direct research and development expenses | 3.48M | the three months ended June 30, 2026 filing | — |
| GlyphAllo | 12.8M | the three months ended June 30, 2026 filing | — |
| GlyphAllo direct research and development expenses | 12.8M | the three months ended June 30, 2026 filing | — |
| Gross proceeds from IPO | 260M | May 2026 | — |
| Preclinical and early discovery assets | 1.41M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPTX
this stock
Seaport Therapeutics, Inc.
|
$980.14M | — | — | — | 7.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 12
Seaport Therapeutics ended Q3 with just north of $403 million, providing runway into 2029 ahead of a Glyph Allo top-line readout in the first half of 2027 and a Glyph-Ago Phase 2A readout in early 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPTX | -14.1% | -7.2% | +0.7% | -6.6% | — |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -10.2% | -1.7% | +4.1% | -3.2% | — |